Investment Rating - The report assigns a "Buy" rating to the company with a current price of HKD 12.20 and a fair value of HKD 18.74 [5]. Core Insights - The company is approaching commercialization of its first product, ABSK021, which has received approval from China's NMPA and is under review by the FDA for a specific indication [5]. - The company reported a revenue of RMB 612 million for 2025, reflecting a year-over-year growth of 21%, alongside a significant increase in adjusted profit [5]. - The company has a robust pipeline with multiple candidates in various stages of clinical development, which supports future growth potential [5]. Financial Forecast - The forecasted revenues for 2026, 2027, and 2028 are RMB 571 million, RMB 375 million, and RMB 726 million, respectively, with corresponding EPS of RMB 0.12, -0.29, and -0.03 [4][5]. - The company is expected to experience a dramatic revenue growth rate of 2,544.2% in 2024, followed by a more moderate growth of 21.5% in 2025, and a decline in subsequent years [4][8]. - The EBITDA for 2024 is projected at RMB 103 million, with a significant drop expected in 2027 to -RMB 199 million [4].